Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A landmark in drug discovery based on complex natural product synthesis.
Kawano S, Ito K, Yahata K, Kira K, Abe T, Akagi T, Asano M, Iso K, Sato Y, Matsuura F, Ohashi I, Matsumoto Y, Isomura M, Sasaki T, Fukuyama T, Miyashita Y, Kaburagi Y, Yokoi A, Asano O, Owa T, Kishi Y. Kawano S, et al. Among authors: asano o. Sci Rep. 2019 Jun 17;9(1):8656. doi: 10.1038/s41598-019-45001-9. Sci Rep. 2019. PMID: 31209263 Free PMC article.
E3024, 3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one tosylate, is a novel, selective and competitive dipeptidyl peptidase-IV inhibitor.
Yasuda N, Nagakura T, Inoue T, Yamazaki K, Katsutani N, Takenaka O, Clark R, Matsuura F, Emori E, Yoshikawa S, Kira K, Ikuta H, Okada T, Saeki T, Asano O, Tanaka I. Yasuda N, et al. Among authors: asano o. Eur J Pharmacol. 2006 Oct 24;548(1-3):181-7. doi: 10.1016/j.ejphar.2006.08.011. Epub 2006 Aug 16. Eur J Pharmacol. 2006. PMID: 16973152
Ten-Gram-Scale Total Synthesis of the Anticancer Drug Candidate E7130 to Supply Clinical Trials.
Kaburagi Y, Kira K, Yahata K, Iso K, Sato Y, Matsuura F, Ohashi I, Matsumoto Y, Isomura M, Sasaki T, Fukuyama T, Miyashita Y, Azuma H, Iida D, Ishida T, Itano W, Matsuda M, Matsukura M, Murai N, Nagao S, Seki M, Yamamoto A, Yamamoto Y, Yoneda N, Watanabe Y, Kamada A, Kayano A, Tagami K, Asano O, Owa T, Kishi Y. Kaburagi Y, et al. Among authors: asano o. Org Lett. 2024 Apr 12;26(14):2837-2842. doi: 10.1021/acs.orglett.3c03663. Epub 2024 Jan 22. Org Lett. 2024. PMID: 38252895
Anti-endotoxin activity of a novel synthetic lipid A analog.
Kawata T, Bristol JR, Rose JR, Rossignol DP, Christ WJ, Asano O, Dubuc GR, Gavin WE, Hawkins LD, Kishi Y, et al. Kawata T, et al. Among authors: asano o. Prog Clin Biol Res. 1995;392:499-509. Prog Clin Biol Res. 1995. PMID: 8524958
First-in-human study of E7130 (a tumor microenvironment-ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose-escalation part.
Doi T, Matsubara N, Naito Y, Kuboki Y, Harano K, Ono M, Urasaki T, Ohmoto A, Kawanai T, Hisai T, Ikezawa H, Shiba S, Ito K, Semba T, Asano O, Takahashi S. Doi T, et al. Among authors: asano o. Cancer. 2023 Aug 1;129(15):2348-2359. doi: 10.1002/cncr.34788. Epub 2023 Apr 20. Cancer. 2023. PMID: 37080942 Clinical Trial.
2-Alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: their synthesis and structure-activity relationships toward hepatic glucose production induced via agonism of the A(2B) receptor.
Harada H, Asano O, Hoshino Y, Yoshikawa S, Matsukura M, Kabasawa Y, Niijima J, Kotake Y, Watanabe N, Kawata T, Inoue T, Horizoe T, Yasuda N, Minami H, Nagata K, Murakami M, Nagaoka J, Kobayashi S, Tanaka I, Abe S. Harada H, et al. Among authors: asano o. J Med Chem. 2001 Jan 18;44(2):170-9. doi: 10.1021/jm990499b. J Med Chem. 2001. PMID: 11170626
21 results